Search Result

Results for "

bile acid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apical Sodium-Dependent Bile Acid Transporter (17) G protein-coupled Bile Acid Receptor 1 (51) 5 alpha Reductase (1) 5-HT Receptor (1) Acetyl-CoA Carboxylase (2) Akt (13) Aminotransferases (Transaminases) (3) AMPK (2) Androgen Receptor (1) Angiotensin-converting Enzyme (ACE) (2) Antibiotic (12) Apoptosis (45) Atg8/LC3 (2) ATM/ATR (1) Autophagy (22) Bacterial (28) Bcl-2 Family (9) BCL6 (4) Biochemical Assay Reagents (27) Calcium Channel (11) Caspase (15) CETP (1) Cholecystokinin Receptor (4) Collagen (4) Constitutive Androstane Receptor (2) COX (1) Cytochrome P450 (10) Dengue Virus (3) DNA/RNA Synthesis (5) Drug Derivative (13) Drug Intermediate (4) Drug Isomer (3) Drug Metabolite (24) Endogenous Metabolite (192) Ephrin Receptor (2) Epigenetic Reader Domain (2) ERK (1) Estrogen Receptor/ERR (1) Factor Xa (1) Ferrochelatase (2) Ferroptosis (9) Flavivirus (3) Fluorescent Dye (4) FOXO (2) Fungal (3) FXR (55) GLP Receptor (2) Glutathione Peroxidase (1) Glutathione Reductase (GR) (1) Glycosyltransferase (1) HBV (10) Hippo (MST) (1) Histamine Receptor (4) HIV Protease (1) HMG-CoA Reductase (HMGCR) (1) Indoleamine 2,3-Dioxygenase (IDO) (2) Integrin (3) Interleukin Related (13) Isotope-Labeled Compounds (53) LDLR (3) Leukotriene Receptor (3) Liposome (2) LPL Receptor (13) mAChR (2) Mas-related G-protein-coupled Receptor (MRGPR) (1) MDM-2/p53 (9) Microtubule/Tubulin (2) Mitochondrial Metabolism (2) MMP (1) MOFs (1) mRNA (2) mTOR (1) Na+/HCO3- Cotransporter (1) Necroptosis (2) NF-κB (12) Nucleoside Antimetabolite/Analog (3) Opioid Receptor (1) Orphan GPCR (1) Osteopontin (1) P-glycoprotein (15) p38 MAPK (5) p62 (2) Parasite (3) PARP (7) PDGFR (1) Peptide-Drug Conjugates (PDCs) (1) Phosphatase (2) PI3K (13) PKA (7) Potassium Channel (1) Pregnane X Receptor (PXR) (2) Prostaglandin Receptor (1) PROTACs (1) Proteasome (2) Reactive Oxygen Species (ROS) (12) Reference Standards (73) ROCK (2) ROR (6) Sirtuin (1) STAT (4) TGF-beta/Smad (3) TNF Receptor (8) Toll-like Receptor (TLR) (1) Transmembrane Glycoprotein (1) TRP Channel (2) VD/VDR (1) VEGFR (1) β-glucuronidase (1)
By Research Areas:	Cancer (69) Cardiovascular Disease (20) Endocrinology (18) Infection (38) Inflammation/Immunology (84) Metabolic Disease (263) Neurological Disease (28)
Click Chemistry:	Azide (1) Alkynes (1)
Oligonucleotides:	Cosolvents (1) Emulsifiers (1) mRNA (2) Cholesterol (3) pH Modifiers (1)

437

Inhibitors & Agonists

Bibliotecas de Screening

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

172

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-B0172

Lithocholic acid 15+ Cited Publications 3α-Hydroxy-5β-cholanic acid	Autophagy Endogenous Metabolite Apoptosis FXR	Metabolic Disease Inflammation/Immunology Cancer
Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a FXR antagonist and a PXR/SXR agonist .

HY-N0593

Deoxycholic acid 25+ Cited Publications Cholanoic acid; Desoxycholic acid	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-13771

Ursodeoxycholic acid 25+ Cited Publications Ursodeoxycholate; Ursodiol; UDCA	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-N2027

Taurochenodeoxycholic acid 5+ Cited Publications 12-Deoxycholyltaurine	Caspase Apoptosis Endogenous Metabolite	Inflammation/Immunology
Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties .

HY-N0593A

Deoxycholic acid sodium salt 25+ Cited Publications Sodium deoxycholate	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-41324

7-keto-Deoxycholic acid 1 Publications Verification	Drug Metabolite	Others
7-keto-Deoxycholic acid is a metabolite of bile acids in Clostridium absonum. 7-keto-Deoxycholic acid is also converted from Lactobacillus and Bifidobacterium with specific condition .

HY-B0172B

Isolithocholic acid 3β-Hydroxy-5β-cholanic acid; 3-Epilithocholic acid; β-Lithocholic acid	Endogenous Metabolite	Endocrinology
Isolithocholic acid (β-Lithocholic acid) is an isomer of Lithocholic acid. Isolithocholic acid, a bile acid, is formed by microbial metabolism of Lithocholic acid or Lithocholic acid 3α-sulfate .

HY-125801

3-Oxo-5β-cholanoic acid 1 Publications Verification Dehydrolithocholic acid; 3-oxoLCA	ROR	Inflammation/Immunology
3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (K_d=1.13 μM) .

HY-116374

Glycolithocholic acid 2 Publications Verification Lithocholylglycine	Endogenous Metabolite	Inflammation/Immunology
Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-N9933

Tauro-β-muricholic acid 4 Publications Verification TβMCA	FXR Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC₅₀=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis .

HY-121238

Hyocholic acid 2 Publications Verification	FXR G protein-coupled Bile Acid Receptor 1	Metabolic Disease
Hyocholic Acid is a bile acid found in pig. Hyocholic Acid can also be found in urine samples from patients with cholestasis. Hyocholic Acid promotes GLP-1 secretion via activating TGR5 and inhibiting FXR in enteroendocrine cells. Hyocholic Acid is known for its exceptional resistance to type 2 diabetes .

HY-N9457

Norcholic acid 1 Publications Verification	Others	Metabolic Disease Endocrinology
Norcholic acid is a normal minorbile C23 bile acid having four side chain and exsits in human urine and meconium. Norcholic acid can become prominent under certain pathological conditions. Norcholic acid is efficiently absorbed from intestine and quickly excreted into the bile but not into urine .

HY-N7387

3-Oxocholic acid 3-Dehydrocholic acid	Endogenous Metabolite	Metabolic Disease
3-Oxocholic acid is an oxo-bile acid metabolite and also a major degradation product from cholic by C. perfringens in the intestine. 3-Oxocholic acid is steroid acid found predominantly in bile of mammals .

HY-135747

Gut restricted-7 5+ Cited Publications GR-7	Bacterial	Infection
Gut restricted-7 (GR-7) is a potent, covalent and orally active pan-bile salt hydrolase (BSH) inhibitor. Gut restricted-7 has a tissue-selective and is restricted to the gut. Gut restricted-7 decreases gut bacterial BSHs and decreases deconjugated bile acid levels in feces of mice .

HY-126995

Glycohyodeoxycholic acid	Endogenous Metabolite	Metabolic Disease
Glycohyodeoxycholic acid is a glycine-conjugated bile acid and also a metabolite of Hyodeoxycholic acid (HY-N0169). The serum level of Glycohyodeoxycholic acid is negatively correlated with the severity of non-alcoholic fatty liver disease. Glycohyodeoxycholic acid can be used in research related to non-alcoholic fatty liver disease .

HY-113478

3β-Ursodeoxycholic acid 1 Publications Verification Isoursodeoxycholic acid	Drug Metabolite	Metabolic Disease
3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) is a bile acid. 3β-Ursodeoxycholic acid shows good tolerance and well intestinal absorption by oral adminstation. 3β-Ursodeoxycholic acid can be isomerized by intestinal and hepatic enzymes to yield UDCA .

HY-114360A

Taurohyodeoxycholic acid sodium 2 Publications Verification	Interleukin Related TNF Receptor	Inflammation/Immunology
Taurohyodeoxycholic acid (THDCA) sodium is the taurine-conjugated form of the secondary bile acid hyodeoxycholic acid. Taurohyodeoxycholic acid can also reduce the activity and expression of myeloperoxidase TNF-α and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model.

HY-13771A

Ursodeoxycholic acid sodium 25+ Cited Publications Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Cancer
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-N1429

Taurochenodeoxycholic acid sodium 5+ Cited Publications 12-Deoxycholyltaurine sodium	Apoptosis Endogenous Metabolite	Inflammation/Immunology
Taurochenodeoxycholic acid (12-Deoxycholyltaurine) sodium is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid sodium induces apoptosis and shows obvious anti-inflammatory and immune regulation properties .

HY-N8332

Bile extract Ox bile extract	Bacterial DNA/RNA Synthesis	Infection
Bile extract (Ox bile extract) is a complex mixture of substances, containing bile acids, cholesterol, and bilirubin. Bile extract has antimicrobial activity and can induce DNA damage and degrade viral and bacterial membranes. Bile extract can be used in bacterial culture media as a selective inhibitor for the isolation and identification of pathogens .

HY-N0169B

Murideoxycholic acid 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
Murideoxycholic acid is a 6 beta-hydroxylated bile acid .

HY-W587530

6-Oxolithocholic acid 6-Ketolithocholic acid	Endogenous Metabolite Apoptosis	Endocrinology
6-Oxolithocholic acid is a bile acid metabolite derived from Lithocholic acid (HY-B0172). 6-Oxolithocholic acid has high cytotoxicity and can induce apoptosis, especially in hepatocytes. 6-Oxolithocholic acid can participate in the regulation of bile acid metabolism and synthesis and affect the metabolic pathway of cholesterol. 6-Oxolithocholic acid can be used to study the role of bile acids in health and disease, especially in the context of digestive and liver diseases .

HY-N15721

Tryptophan-cholic acid Trp-CA	Orphan GPCR GLP Receptor	Metabolic Disease
Tryptophan-cholic acid (Trp-CA) is a microbial *amino acid-conjugated bile* acid that acts as an endogenous ligand and agonist (EC₅₀=9.6 μM) for the orphan G protein-coupled receptor (GPCR) MRGPRE (Mas-related G protein-coupled receptor family member E). Tryptophan-cholic acid is orally effective but has poor oral absorption and does not cross the blood-brain barrier. Tryptophan-cholic acid promotes the secretion of glucagon-like peptide GLP-1**, thereby improving glucose tolerance in diabetic mice. Tryptophan-cholic acid improves glucose tolerance, promotes insulin secretion, and alleviates high-fat diet-induced hepatic steatosis without causing pruritus side effects. Tryptophan-cholic acid is primarily used in research on type 2 diabetes (T2D) .

HY-N0468

Rebaudioside D 1 Publications Verification	FXR Acetyl-CoA Carboxylase	Metabolic Disease
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-B0172S

Lithocholic acid-d4 1 Publications Verification 3α-Hydroxy-5β-cholanic acid-d₄	Isotope-Labeled Compounds Autophagy Apoptosis	Metabolic Disease
Lithocholic acid-d₄ is the deuterium labeled Lithocholic acid, which is a toxic secondary bile acid .

HY-B0172R

Lithocholic acid (Standard) 15+ Cited Publications 3α-Hydroxy-5β-cholanic acid (Standard)	Reference Standards Autophagy Endogenous Metabolite Apoptosis FXR	Metabolic Disease Cancer
Lithocholic acid (Standard) is the analytical standard of Lithocholic acid. This product is intended for research and analytical applications. Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a FXR antagonist and a PXR/SXR agonist .

HY-B1899A

Taurodeoxycholic acid sodium hydrate 3 Publications Verification Taurodeoxycholate sodium hydrate	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway .

HY-106539

Colesevelam hydrochloride	FXR G protein-coupled Bile Acid Receptor 1 GLP Receptor	Metabolic Disease Cancer
Colesevelam hydrochloride is an orally active bile acid sequestrant, lipid-lowering agent, and glycemic control agent. Colesevelam hydrochloride binds bile acids in the gastrointestinal tract to form nonabsorbable complexes, interrupts enterohepatic recirculation and increases fecal bile acid elimination. Colesevelam hydrochloride modulates FXR, TGR5, and Cyp7a1 activity and triggers cAMP signaling and GLP-1 release. Colesevelam hydrochloride alters hepatic lipid and glucose metabolism, suppresses hepatic glycogenolysis, reduces hepatic triglyceride and cholesterol levels, and increases LDL-C (low-density lipoprotein cholesterol) clearance. Colesevelam hydrochloride can be used for the research of type 2 diabetes mellitus, hypercholesterolemia, and alcohol-related liver disease .

HY-160929

Linafexor CS-0159	FXR	Inflammation/Immunology
Linafexor (CS-0159) is a FXR agonist and bile acid homeostasis modulator. Linafexor exerts its effects by activating FXR, a regulator of liver function. Linafexor is applicable to research related to primary sclerosing cholangitis (PSC). Linafexor is also suitable for research in the field of metabolic dysfunction-associated steatohepatitis (MASH) .

HY-W747583

Apocholic acid	Endogenous Metabolite	Metabolic Disease
Apocholic acid is a bile acid belonging to steroidal organic acids. Apocholic acid is an endogenous metabolite .

HY-125138

ω-Muricholic Acid 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
ω-Muricholic Acid is a bile acid. ω-Muricholic Acid is a metabolite of chenodeoxycholic acid in jaundiced mice. ω-Muricholic Acid can be used for the research of surgically jaundiced .

HY-113259

7α-Hydroxy-4-cholesten-3-one	Endogenous Metabolite	Metabolic Disease
7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-W353102

Estradiol 17-(β-D-Glucuronide)	Endogenous Metabolite P-glycoprotein	Metabolic Disease
Estradiol 17-(β-D-Glucuronide) is a D-ring glucuronide metabolite of natural estrogen formed in the liver. Estradiol 17-(β-D-Glucuronide) is a substrate of the organic anion-transporting polypeptide family (Oatp) and multidrug resistance-associated protein 2 (Mrp2). Estradiol 17-(β-D-Glucuronide) regulates MRP8-mediated transport processes and inhibits MRP8-mediated transport of dehydroepiandrosterone 3-sulfate and taurocholic acid. Estradiol 17-(β-D-Glucuronide) induces immediate, reversible reduction of bile flow and acute intrahepatic cholestasis in female rats without altering the bile acid composition in bile. Estradiol 17-(β-D-Glucuronide) can be used in studies related to intrahepatic cholestasis .

HY-48814

3-Epideoxycholic acid	Bacterial FXR	Infection Inflammation/Immunology
3-Epideoxycholic acid is a secondary bile acid and a microbial metabolite of Deoxycholic acid (HY-N0593). 3-Epideoxycholic acid targets FXR in dendritic cells, reduces their immunostimulatory properties, promotes the generation of Treg cells, and exerts anti-inflammatory activity. 3-Epideoxycholic acid can promote the growth of the bacterium Bacteroides. 3-Epideoxycholic acid can be used in research related to inflammatory and immune diseases as well as bacterial infections .

HY-125469

ICA-105665 PF-04895162	Potassium Channel	Neurological Disease
ICA-105665 (PF-04895162) is a potent and orally active neuronal Kv7.2/7.3 and Kv7.3/7.5 potassium channels opener. ICA-105665 inhibits liver mitochondrial function and bile salt export protein (BSEP) transport (IC₅₀ of 311 μM). ICA-105665 can penetrate the blood-brain barrier and has antiseizure effects .

HY-N8268

Nordeoxycholic acid 3α,12α-Dihydroxynorcholanic acid	Others	Metabolic Disease
Nordeoxycholic acid is a 23-carbon bile acid. Nordeoxycholic acid is a norcholic acid metabolite and a steroid human metabolite .

HY-43470

3α,12β-Dihydroxycholanoic acid	Endogenous Metabolite	Metabolic Disease
3α,12β-Dihydroxycholanoic acid is a bile acid that can be isolated from urine specimens of healthy humans .

HY-W018512

7-Ketolithocholic acid 4 Publications Verification 3α-Hydroxy-7-oxo-5β-cholanic acid	Endogenous Metabolite	Metabolic Disease
7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-158766

3-sucCA 3-Succinylated cholic acid	Endogenous Metabolite Bacterial	Infection Inflammation/Immunology
3-sucCA is an orally available bacterial bile acid that exerts anti-MASH effects by promoting the growth of Akkermansia muciniphila. By remodeling the intestinal microbiota and promoting the growth of Akkermansia, 3-sucCA can improve intestinal barrier damage and reduce chronic low-level inflammation, thereby alleviating the progression of metabolic dysfunction-associated steatohepatitis (MASH). 3-sucCA accelerates the synthesis of cell wall peptidoglycan and has in vivo efficacy in the mouse MAFL-MASH model. 3-sucCA levels are low in the MAFLD model and are mainly used in the study of MASH .

HY-113482

1β-Hydroxydeoxycholic acid 1β-OH-DCA	Endogenous Metabolite Cytochrome P450	Metabolic Disease
1β-Hydroxydeoxycholic acid (1β-OH-DCA), a secondary bile acid, is a CYP3A biomarker. Deoxycholic acid is specifically metabolized into 1β-Hydroxydeoxycholic acid by CYP3A4 and CYP3A7 using recombinant human CYP450 enzymes .

HY-W399297

Isodeoxycholic acid 1 Publications Verification 7α,12α-Dihydroxycholanoic acid	Endogenous Metabolite	Metabolic Disease
Isodeoxycholic acid (7α,12α-Dihydroxycholanoic acid) is a 3β-hydroxylated secondary bile acid. Isodeoxycholic acid is produced by epimerization of deoxycholic acid by intestinal bacteria. Isodeoxycholic acid is detectable in feces, mainly existing as saponifiable conjugates with long-chain fatty acids. Isodeoxycholic acid participates in the regulation of intestinal physiology .

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-116374A

Glycolithocholic acid sodium 2 Publications Verification Lithocholylglycine sodium	Endogenous Metabolite	Metabolic Disease
Glycolithocholic acid (Lithocholylglycine) sodium is the sodium salt of Glycolithocholic acid. Glycolithocholic acid is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-158000

Bile acid probe 1	Fluorescent Dye	Metabolic Disease
Bile acid probe 1, a clickable and photoreactive probe for Bile acid, contains ester linkage .

HY-N0593R

Deoxycholic acid (Standard) 20+ Cited Publications Cholanoic acid(Standard); Desoxycholic acid (Standard)	Reference Standards G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid (Standard) is the analytical standard of Deoxycholic acid. This product is intended for research and analytical applications. Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-N0593AR

Deoxycholic acid sodium salt (Standard) Sodium deoxycholate (Standard)	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Reference Standards	Metabolic Disease
Deoxycholic acid sodium salt (Standard) is the analytical standard of Deoxycholic acid sodium salt. This product is intended for research and analytical applications. Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-N11416

Glycodehydrocholic acid	Endogenous Metabolite	Metabolic Disease Endocrinology Cancer
Glycodehydrocholic acid is a bile acid glycine conjugate. Glycodehydrocholic acid is used to diagnose cancer and other diseases .

HY-W018512R

7-Ketolithocholic acid (Standard) 3α-Hydroxy-7-oxo-5β-cholanic acid (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
7-Ketolithocholic acid (Standard) is the analytical standard of 7-Ketolithocholic acid. This product is intended for research and analytical applications. 7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-148795

Ritivixibat	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Ritivixibat is an apical sodium-dependent bile acid transporter (ASBT/IBAT) inhibitor. Ritivixibat blocks ASBT/IBAT function, thereby reducing bile acid reabsorption, regulating bile acid homeostasis and alleviating liver injury. Ritivixibat protects cholangiocytes from damage caused by cytotoxic bile acids. Ritivixibat is applicable to research related to primary sclerosing cholangitis .

HY-N0324F

Cholic acid-Biotin	Fluorescent Dye	Metabolic Disease
Cholic acid-Biotin is a biotin-labeled Cholic acid (HY-N0324). Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid has orally activity .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-B0172

Lithocholic acid 15+ Cited Publications 3α-Hydroxy-5β-cholanic acid	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Anti-aging Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Autophagy Endogenous Metabolite Apoptosis FXR
Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a FXR antagonist and a PXR/SXR agonist .

HY-A0190

Caerulein Maximum Cited Publications 132 Publications Verification Ceruletide; Cerulein; FI-6934	Cardiovascular Disease Alkaloids Structural Classification Animals Classification of Application Fields Disease Research Fields Endocrinology Indole Alkaloids Source Classification	Cholecystokinin Receptor
Caerulein is a decapeptide and a potent cholecystokinin receptor agonist. Caerulein is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

HY-N0593

Deoxycholic acid 25+ Cited Publications Cholanoic acid; Desoxycholic acid	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite
Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-13771

Ursodeoxycholic acid 25+ Cited Publications Ursodeoxycholate; Ursodiol; UDCA	Human Gut Microbiota Metabolites Other disease Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-N2027

Taurochenodeoxycholic acid 5+ Cited Publications 12-Deoxycholyltaurine	Microorganisms Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	Caspase Apoptosis Endogenous Metabolite
Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties .

HY-76847

Chenodeoxycholic Acid 20+ Cited Publications CDCA	Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	FXR Endogenous Metabolite Autophagy
Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N0324

Cholic acid 15+ Cited Publications	Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active .

HY-N0593A

Deoxycholic acid sodium salt 25+ Cited Publications Sodium deoxycholate	Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite
Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-N0169

Hyodeoxycholic acid 5+ Cited Publications HDCA	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite
Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC₅₀ of 31.6 µM in CHO cells.

HY-135772

12-Ketodeoxycholic acid 12-Ketolithocholic acid	Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
12-Ketodeoxycholic acid (12-Ketolithocholic acid) is a bile acid, metabolite from kidney. 12-Ketodeoxycholic acid can be a detectable marker for evidence of kidney injury

HY-41324

7-keto-Deoxycholic acid 1 Publications Verification	Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Drug Metabolite
7-keto-Deoxycholic acid is a metabolite of bile acids in Clostridium absonum. 7-keto-Deoxycholic acid is also converted from Lactobacillus and Bifidobacterium with specific condition .

HY-B0172B

Isolithocholic acid 3β-Hydroxy-5β-cholanic acid; 3-Epilithocholic acid; β-Lithocholic acid	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Steroids Source Classification	Endogenous Metabolite
Isolithocholic acid (β-Lithocholic acid) is an isomer of Lithocholic acid. Isolithocholic acid, a bile acid, is formed by microbial metabolism of Lithocholic acid or Lithocholic acid 3α-sulfate .

HY-N1424

Glycoursodeoxycholic acid 3 Publications Verification GUDCA; Ursodeoxycholylglycine	Structural Classification Endogenous metabolite Steroids Source Classification	Endogenous Metabolite
Glycoursodeoxycholic acid, a acyl glycine and a bile acid-glycine conjugate, is a metabolite of ursodeoxycholic acid.

HY-116374

Glycolithocholic acid 2 Publications Verification Lithocholylglycine	Human Gut Microbiota Metabolites Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-N9933

Tauro-β-muricholic acid 4 Publications Verification TβMCA	Structural Classification Human Gut Microbiota Metabolites Animals Endogenous metabolite Steroids Source Classification	FXR Apoptosis
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC₅₀=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis .

HY-N9457

Norcholic acid 1 Publications Verification	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Others
Norcholic acid is a normal minorbile C23 bile acid having four side chain and exsits in human urine and meconium. Norcholic acid can become prominent under certain pathological conditions. Norcholic acid is efficiently absorbed from intestine and quickly excreted into the bile but not into urine .

HY-N7387

3-Oxocholic acid 3-Dehydrocholic acid	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
3-Oxocholic acid is an oxo-bile acid metabolite and also a major degradation product from cholic by C. perfringens in the intestine. 3-Oxocholic acid is steroid acid found predominantly in bile of mammals .

HY-126995

Glycohyodeoxycholic acid	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Glycohyodeoxycholic acid is a glycine-conjugated bile acid and also a metabolite of Hyodeoxycholic acid (HY-N0169). The serum level of Glycohyodeoxycholic acid is negatively correlated with the severity of non-alcoholic fatty liver disease. Glycohyodeoxycholic acid can be used in research related to non-alcoholic fatty liver disease .

HY-N0324A

Cholic acid sodium 15+ Cited Publications Sodium cholate	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Cholic acid sodium is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid sodium is orally active .

HY-13771A

Ursodeoxycholic acid sodium 25+ Cited Publications Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	Microorganisms Classification of Application Fields Metabolic Disease Inflammation/Immunology Disease Research Fields Steroids Source Classification	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-N1429

Taurochenodeoxycholic acid sodium 5+ Cited Publications 12-Deoxycholyltaurine sodium	Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	Apoptosis Endogenous Metabolite
Taurochenodeoxycholic acid (12-Deoxycholyltaurine) sodium is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid sodium induces apoptosis and shows obvious anti-inflammatory and immune regulation properties .

HY-113212

Ursocholic acid 1 Publications Verification	Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite Apoptosis
Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis .

HY-124265

4β-Hydroxycholesterol	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
4β-Hydroxycholesterol is a major Cholesterol (HY-N0322) metabolite and a precursor in the synthesis of bile acids that is found in human circulation .

HY-N0169B

Murideoxycholic acid 1 Publications Verification	Animals Classification of Application Fields Metabolic Disease Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Murideoxycholic acid is a 6 beta-hydroxylated bile acid .

HY-N15721

Tryptophan-cholic acid Trp-CA	Triterpenes Structural Classification Terpenoids Endogenous metabolite Source Classification	Orphan GPCR GLP Receptor
Tryptophan-cholic acid (Trp-CA) is a microbial *amino acid-conjugated bile* acid that acts as an endogenous ligand and agonist (EC₅₀=9.6 μM) for the orphan G protein-coupled receptor (GPCR) MRGPRE (Mas-related G protein-coupled receptor family member E). Tryptophan-cholic acid is orally effective but has poor oral absorption and does not cross the blood-brain barrier. Tryptophan-cholic acid promotes the secretion of glucagon-like peptide GLP-1**, thereby improving glucose tolerance in diabetic mice. Tryptophan-cholic acid improves glucose tolerance, promotes insulin secretion, and alleviates high-fat diet-induced hepatic steatosis without causing pruritus side effects. Tryptophan-cholic acid is primarily used in research on type 2 diabetes (T2D) .

HY-N0468

Rebaudioside D 1 Publications Verification	Structural Classification other families Classification of Application Fields Terpenoids Metabolic Disease Diterpenoids Plants Disease Research Fields Sweeteners Source Classification Food Research	FXR Acetyl-CoA Carboxylase
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-113315

3b-Hydroxy-5-cholenoic acid	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
3β-Hydroxy-5-cholenoic acid is a steroidal monohydroxy bile acid and serves as a substrate for sulfation reactions. It is applicable to the research of extrahepatic biliary atresia and recurrent intrahepatic cholestasis of pregnancy .

HY-115433

α-Muricholic acid 1 Publications Verification	Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Steroids Source Classification	Endogenous Metabolite
α-Muricholic acid is the most abundant primary bile acid in rodents .

HY-B0172R

Lithocholic acid (Standard) 15+ Cited Publications 3α-Hydroxy-5β-cholanic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Anti-aging Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Reference Standards Autophagy Endogenous Metabolite Apoptosis FXR
Lithocholic acid (Standard) is the analytical standard of Lithocholic acid. This product is intended for research and analytical applications. Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a FXR antagonist and a PXR/SXR agonist .

HY-B1899A

Taurodeoxycholic acid sodium hydrate 3 Publications Verification Taurodeoxycholate sodium hydrate	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite
Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway .

HY-N10319

Artepillin C	Ketones, Aldehydes, Acids Plants Compositae Artemisia capillaris Thunb. Source Classification	Epigenetic Reader Domain Necroptosis TRP Channel
Artepillin C is an orally active CREB/CRTC2 inhibitor and TRPA1 covalent agonist (EC₅₀=1.8 μM). Artepillin C inhibits CREB/CRTC2-mediated gene transcription and downregulates BMAL1 expression to regulate glucose and lipid metabolism. Artepillin C can also activate TRPA1 channels to induce spicy taste signals. Artepillin C can inhibit tumor cell proliferation, induce necroptosis, improve insulin resistance and inhibit liver lipid synthesis. Artepillin C can be used in the study of metabolic syndrome, tumor prevention and treatment, and inflammation .

HY-133890

Tauro-α-muricholic acid 2 Publications Verification T-α-MCA	Structural Classification Human Gut Microbiota Metabolites Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite FXR
Tauro-α-muricholic acid (T-α-MCA) is a Taurine (HY-B0351)-conjugated primary Bile acid. Tauro-α-muricholic acid is a FXR antagonist with an IC₅₀ of 28 µM. Tauro-α-muricholic acid attenuates other bile acid-activated FXR signaling. Tauro-α-muricholic acid can be used in the research of Alzheimer's disease, glucose metabolism, and lipid metabolism .

HY-N1427

Glycodeoxycholate Sodium 3 Publications Verification Sodium glycyldeoxycholate	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Glycodeoxycholate Sodium (Sodium glycyldeoxycholate) is a bile salt. Glycodeoxycholate Sodium has cytotoxicity to cancer cell, changes the permeability of the pancreatic duct and decreases glucose levels .

HY-W747583

Apocholic acid	Structural Classification Endogenous metabolite Steroids Source Classification	Endogenous Metabolite
Apocholic acid is a bile acid belonging to steroidal organic acids. Apocholic acid is an endogenous metabolite .

HY-125138

ω-Muricholic Acid 1 Publications Verification	Structural Classification Microorganisms Classification of Application Fields Metabolic Disease Disease Research Fields Steroids Source Classification	Endogenous Metabolite
ω-Muricholic Acid is a bile acid. ω-Muricholic Acid is a metabolite of chenodeoxycholic acid in jaundiced mice. ω-Muricholic Acid can be used for the research of surgically jaundiced .

HY-113259

7α-Hydroxy-4-cholesten-3-one	Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-W353102

Estradiol 17-(β-D-Glucuronide)	Structural Classification Monophenols Classification of Application Fields Phenols Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Steroids Source Classification	Endogenous Metabolite P-glycoprotein
Estradiol 17-(β-D-Glucuronide) is a D-ring glucuronide metabolite of natural estrogen formed in the liver. Estradiol 17-(β-D-Glucuronide) is a substrate of the organic anion-transporting polypeptide family (Oatp) and multidrug resistance-associated protein 2 (Mrp2). Estradiol 17-(β-D-Glucuronide) regulates MRP8-mediated transport processes and inhibits MRP8-mediated transport of dehydroepiandrosterone 3-sulfate and taurocholic acid. Estradiol 17-(β-D-Glucuronide) induces immediate, reversible reduction of bile flow and acute intrahepatic cholestasis in female rats without altering the bile acid composition in bile. Estradiol 17-(β-D-Glucuronide) can be used in studies related to intrahepatic cholestasis .

HY-76847A

Chenodeoxycholic acid sodium 20+ Cited Publications CDCA sodium	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	FXR Autophagy Endogenous Metabolite
Chenodeoxycholic acid sodium is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-W403933

12-Ketochenodeoxycholic acid	Structural Classification Human Gut Microbiota Metabolites Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite
12-Ketochenodeoxycholic acid is an anomalous bile acid and Chenodeoxycholic acid (HY-76847) precursor. 12-Ketochenodeoxycholic acid can be used for the research of hepatobiliary diseases .

HY-76847R

Chenodeoxycholic Acid (Standard) 20+ Cited Publications CDCA (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	Reference Standards FXR Endogenous Metabolite Autophagy
Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-129987

Estradiol 17-(β-D-Glucuronide) sodium	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Steroids Source Classification	Endogenous Metabolite P-glycoprotein
Estradiol 17-(β-D-Glucuronide) sodium is a D-ring glucuronide metabolite of natural estrogen formed in the liver. Estradiol 17-(β-D-Glucuronide) sodium is a substrate of the organic anion-transporting polypeptide family (Oatp) and multidrug resistance-associated protein 2 (Mrp2). Estradiol 17-(β-D-Glucuronide) sodium regulates MRP8-mediated transport processes and inhibits MRP8-mediated transport of dehydroepiandrosterone 3-sulfate and taurocholic acid. Estradiol 17-(β-D-Glucuronide) sodium induces immediate, reversible reduction of bile flow and acute intrahepatic cholestasis in female rats without altering the bile acid composition in bile. Estradiol 17-(β-D-Glucuronide) sodium can be used in studies related to intrahepatic cholestasis .

HY-N8268

Nordeoxycholic acid 3α,12α-Dihydroxynorcholanic acid	Animals Source Classification	Others
Nordeoxycholic acid is a 23-carbon bile acid. Nordeoxycholic acid is a norcholic acid metabolite and a steroid human metabolite .

HY-43470

3α,12β-Dihydroxycholanoic acid	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
3α,12β-Dihydroxycholanoic acid is a bile acid that can be isolated from urine specimens of healthy humans .

HY-W018512

7-Ketolithocholic acid 4 Publications Verification 3α-Hydroxy-7-oxo-5β-cholanic acid	Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-113482

1β-Hydroxydeoxycholic acid 1β-OH-DCA	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite Cytochrome P450
1β-Hydroxydeoxycholic acid (1β-OH-DCA), a secondary bile acid, is a CYP3A biomarker. Deoxycholic acid is specifically metabolized into 1β-Hydroxydeoxycholic acid by CYP3A4 and CYP3A7 using recombinant human CYP450 enzymes .

HY-W399297

Isodeoxycholic acid 1 Publications Verification 7α,12α-Dihydroxycholanoic acid	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Isodeoxycholic acid (7α,12α-Dihydroxycholanoic acid) is a 3β-hydroxylated secondary bile acid. Isodeoxycholic acid is produced by epimerization of deoxycholic acid by intestinal bacteria. Isodeoxycholic acid is detectable in feces, mainly existing as saponifiable conjugates with long-chain fatty acids. Isodeoxycholic acid participates in the regulation of intestinal physiology .

HY-W779068

Chenodeoxycholic acid 3-sulfate disodium	Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Chenodeoxycholic acid 3-sulfate disodium is a bile acid. Chenodeoxycholic acid 3-sulfate disodium level corresponds closely with the extent of hepatic dysfunction .

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Disease markers Endogenous metabolite Steroids Source Classification	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-111769

Taurochenodeoxycholate-3-sulfate	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Taurochenodeoxycholate-3-sulfate is a bile salt found in urine .

HY-133890A

Tauro-α-muricholic acid sodium 2 Publications Verification T-α-MCA sodium	Structural Classification Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite FXR
Tauro-α-muricholic acid sodium (T-α-MCA sodium) is a Taurine (HY-B0351)-conjugated primary Bile acid. Tauro-α-muricholic acid sodium is a FXR antagonist with an IC₅₀ of 28 µM. Tauro-α-muricholic acid sodium attenuates other bile acid-activated FXR signaling. Tauro-α-muricholic acid sodium can be used in the research of Alzheimer's disease, glucose metabolism, and lipid metabolism .

Cat. No.	Nombre del producto	Chemical Structure

HY-N0324S

Cholic acid-d4 3 Publications Verification
Cholic acid-d₄ is the deuterium labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.

HY-76847S

Chenodeoxycholic Acid-d4 1 Publications Verification
Chenodeoxycholic Acid-d₄ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N0593S

Deoxycholic acid-d4 1 Publications Verification
Deoxycholic acid-d₄ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-N1423S

Glycocholic acid-d4

Glycocholic acid-d₄ is the deuterium labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

HY-B0172S

Lithocholic acid-d4 1 Publications Verification
Lithocholic acid-d₄ is the deuterium labeled Lithocholic acid, which is a toxic secondary bile acid .

HY-113478S

Ursodeoxycholic acid-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

HY-B0351S

Taurine-d4 1 Publications Verification
Taurine-d₄ is the deuterium labeled Taurine. Taurine, a sulphur-containing amino acid and an organic osmolyte involved in cell volume regulation, provides a substrate for the formation of bile salts, and plays a role in the modulation of intracellular free calcium concentration. Taurine has the ability to activate autophagy in adipocytes .

HY-B1788S

Taurocholic acid-d4 sodium 1 Publications Verification
Taurocholic acid-d₄ (sodium) is the deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) is a bile acid involved in the emulsification of fats.

HY-124265S

4β-Hydroxycholesterol-d7
4β-Hydroxycholesterol-d₇ is the deuterium labeled 4β-Hydroxycholesterol (HY-124265). 4β-Hydroxycholesterol is a major Cholesterol (HY-N0322) metabolite and a precursor in the synthesis of bile acids that is found in human circulation .

HY-N0324S2

Cholic acid-13C
Cholic acid- ¹³C is the ¹³C-labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.

HY-N2334S

Glycochenodeoxycholic acid-d4
Glycochenodeoxycholic acid-d₄ is the deuterium labeled Glycochenodeoxycholic acid. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) induces hepatocyte apoptosis .

HY-124265S2

4β-Hydroxycholesterol-d4
4β-Hydroxycholesterol-d₄ is the deuterium labeled 4β-Hydroxycholesterol (HY-124265) . 4β-Hydroxycholesterol is a major Cholesterol (HY-N0322) metabolite and a precursor in the synthesis of bile acids that is found in human circulation .

HY-B0351S2

Taurine-13C2,15N
Taurine- ¹³C₂, ¹⁵N is the ¹³C- and ¹⁵N- labeled Taurine. Taurine, a sulphur-containing amino acid and an organic osmolyte involved in cell volume regulation, provides a substrate for the formation of bile salts, and plays a role in the modulation of intracellular free calcium concentration. Taurine has the ability to activate autophagy in adipocytes .

HY-N0324S1

Cholic acid-d5
Cholic acid-d₅ is the deuterium labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.

HY-N2027S

Taurochenodeoxycholic acid-d4 sodium
Taurochenodeoxycholic acid-d₄ (sodium) is the deuterium labeled Taurochenodeoxycholic acid. Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties .

HY-B0351S1

Taurine-13C2
Taurine- ¹³C₂ is the ¹³C-labeled Taurine. Taurine, a sulphur-containing amino acid and an organic osmolyte involved in cell volume regulation, provides a substrate for the formation of bile salts, and plays a role in the modulation of intracellular free calcium concentration. Taurine has the ability to activate autophagy in adipocytes .

HY-76847S3

Chenodeoxycholic acid-d5
Chenodeoxycholic acid-d₅ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847S2

Chenodeoxycholic acid-13C
Chenodeoxycholic acid- ¹³C is the ¹³C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N1424S

Glycoursodeoxycholic acid-d4
Glycoursodeoxycholic acid-d₄ (Ursodeoxycholylglycine-d₄) is the deuterium labeled Glycoursodeoxycholic acid. Glycoursodeoxycholic acid, a acyl glycine and a bile acid-glycine conjugate, is a metabolite of ursodeoxycholic acid .

HY-113259S

7α-Hydroxy-4-cholesten-3-one-d7

7α-Hydroxy-4-cholesten-3-one-d₇ is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-N1429S1

Taurochenodeoxycholic acid-d5 sodium
Taurochenodeoxycholic acid-d₅ (sodium) is the deuterium labeled Taurochenodeoxycholic acid sodium. Taurochenodeoxycholic acid sodium salt (12-Deoxycholyltaurine sodium salt) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties .

HY-B1899S

Taurodeoxycholic acid-d5

Taurodeoxycholic acid-d₅ is the deuterium labeled Taurodeoxycholic acid (HY-B1899) . Taurodeoxycholic acid, a bile acid, stabilizes the mitochondrial membrane, decreases free radical formation. Taurodeoxycholic acid inhibits apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid exhibits neuroprotective effect in 3-nitropropionic acid induced mouse model or genetic mouse model of Huntington's disease (HD) .

HY-116374S

Glycolithocholic acid-d4
Glycolithocholic acid-d₄ is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-B1788S1

Taurocholic acid-d4 1 Publications Verification
Taurocholic acid-d₄ is deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) is a bile acid involved in the emulsification of fats.

HY-115433S

α-Muricholic acid-d5
α-Muricholic acid-d₅ is the deuterium labeled α-Muricholic acid. α-Muricholic acid is the most abundant primary bile acid in rodents .

HY-N0593S1

Deoxycholic acid-d5
Deoxycholic acid-d₅ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-N0593S3

Deoxycholic acid-13C
Deoxycholic acid- ¹³C is the ¹³C-labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-113308S1

Taurolithocholic acid-d4

Taurolithocholic acid-d₄ is deuterium labeled Taurolithocholic acid. Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

HY-N0593S2

Deoxycholic acid-d6
Deoxycholic acid-d₆ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-128853S

Taurodeoxycholate-d6 sodium

Taurodeoxycholate-d₆ sodium salt is a bile salt-related anionic detergent. Taurodeoxycholate-d₆ sodium salt is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholate-d₆ sodium salt is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate-d₆ (TDCA) exhibits anti-inflammatory and neuroprotective effects .

HY-13771S1

Ursodeoxycholic acid-13C

Ursodeoxycholic acid- ¹³C is the ¹³C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-76847S1

Chenodeoxycholic Acid-d9
Chenodeoxycholic Acid-d₉ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N0169S

Hyodeoxycholic acid-d5
Hyodeoxycholic acid-d₅ is the deuterium labeled Hyodeoxycholic acid. Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHO cells.

HY-N1429S

Taurochenodeoxycholic acid-d9 sodium
Taurochenodeoxycholic acid-d₉ (sodium) is the deuterium labeled Taurochenodeoxycholic acid sodium. Taurochenodeoxycholic acid sodium salt (12-Deoxycholyltaurine sodium salt) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties .

HY-N1423S1

Glycocholic acid-d5

Glycocholic acid-d₅ is the deuterium labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

HY-124265S1

4β-Hydroxycholesterol-d5
4β-Hydroxycholesterol-d₅ is the deuterium labeled 4β-Hydroxycholesterol (HY-124265). 4β-Hydroxycholesterol is a major Cholesterol (HY-N0322) metabolite and a precursor in the synthesis of bile acids that is found in human circulation .

HY-113308AS1

Taurolithocholic Acid-d5 sodium salt

Taurolithocholic Acid-d₅ (sodium) is the deuterium labeled Taurolithocholic acid sodium salt. Taurolithocholic Acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic Acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic Acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic Acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic Acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic Acid sodium salt not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

HY-143712S1

Allolithocholic Acid-d4

Allolithocholic Acid-d₄ (3α-hydoxy-5α-Cholaoic Acid-d₄, allo-LCA-d₄) is deuterium labeled Allolithocholic acid (HY-143712). Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC₅₀ = 2.7 μM) and RORγt inverse agonist (IC₅₀ = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease .

HY-113212S

Ursocholic acid-d4

Ursocholic acid-d₄ is deuterium labeled Ursocholic acid. Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis .

HY-N15828

Glycochenodeoxycholic acid 3-sulfate-d4 disodium
Glycochenodeoxycholic acid 3-sulfate-d₄ is the deuterium labeled bile acid .

HY-109120S

Odevixibat-d5
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal *apical sodium-dependent bile* acid transporter (ASBT*) inhibitor. Odevixibat decreases cholestatic liver and bile* duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal *apical sodium-dependent bile* acid transporter (ASBT*) inhibitor. Odevixibat decreases cholestatic liver and bile* duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-115433S1

α-Muricholic acid-d4
α-Muricholic acid-d₄ is the deuterium labeled α-Muricholic acid. α-Muricholic acid is the most abundant primary bile acid in rodents .

HY-133890AS

Tauro-α-muricholic acid-d4 sodium

Tauro-α-muricholic acid-d₄ (sodium) is the deuterium labeled Tauro-α-muricholic acid sodium (HY-133890A). Tauro-α-muricholic acid sodium (T-α-MCA sodium) is a Taurine (HY-B0351)-conjugated primary Bile acid. Tauro-α-muricholic acid sodium is a FXR antagonist with an IC₅₀ of 28 µM. Tauro-α-muricholic acid sodium attenuates other bile acid-activated FXR signaling. Tauro-α-muricholic acid sodium can be used in the research of Alzheimer's disease, glucose metabolism, and lipid metabolism .

HY-76847S4

Chenodeoxycholic acid-d2
Chenodeoxycholic acid-d₂ (CDCA-d₂) is deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-W653947

Glycoursodeoxycholic acid-d5
Glycoursodeoxycholic acid-d₅ (Ursodeoxycholylglycine-d₅) is the deuterium labeled Glycoursodeoxycholic acid (HY-N1424). Glycoursodeoxycholic acid, a acyl glycine and a bile acid-glycine conjugate, is a metabolite of ursodeoxycholic acid.

HY-W712932

Chenodeoxycholic Acid-d7
Chenodeoxycholic Acid-d₇ (CDCA-d₇) is the deuterium labeled Chenodeoxycholic Acid (HY-76847). Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N2334AS

Glycochenodeoxycholic acid-d7 sodium

Glycochenodeoxycholic acid-d₇ (sodium) is the deuterium labeled Glycochenodeoxycholic acid (sodium salt). Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) induces hepatocyte apoptosis .

HY-N1429S2

Taurochenodeoxycholic acid-d4-1 sodium
Taurochenodeoxycholic acid-d₄-1 (sodium) is the deuterium labeled Taurochenodeoxycholic acid. Taurochenodeoxycholic acid (12-Deoxycholyltaurine) sodium is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid sodium induces apoptosis and shows obvious anti-inflammatory and immune regulation properties .

HY-B0149S3

Tranexamic acid-13C2,15N
Tranexamic acid- ¹³C₂, ¹⁵N (Cyclocapron- ¹³C₂, ¹⁵N) is the ¹³C₂ and ¹⁵N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones